肾功能不全患者的高敏肌钙蛋白理想基线截断值
该研究为一项FDA前瞻性研究的预设二次分析,纳入2015年4月至2016年4月间29个城市急诊科收治的疑似心肌梗死成人患者,采血时间点为0、1、2-3和6-9小时。在eGFR<15 mL/min/1.73 m²的患者中,基线rule-in截断值120 ng/L对应的特异性为85.0%、阳性预测值为62.5%;将截断值提高至600 ng/L后,整体及各eGFR亚组的特异性和阳性预测值均提高(eGFR<15 mL/min/1.73 m²者特异性93.3%、阳性预测值78.9%),但需观察的患者数增加(79例)。作者认为该eGFR调整的基线rule-in阈值可提高特异性且敏感性相同,并建议在前瞻性队列中进一步研究。
要点
- 在eGFR<15 mL/min/1.73 m²患者中,Siemens Atellica hs-cTnI基线rule-in截断值120 ng/L对应的特异性为85.0%、阳性预测值为62.5%。
- 将基线rule-in截断值提高至600 ng/L后,整体及各eGFR亚组的特异性和阳性预测值均提高,eGFR<15 mL/min/1.73 m²者特异性93.3%、阳性预测值78.9%。
- 提高截断值至600 ng/L后,需进一步观察的患者数为79例(原文报告)。
- 该研究为FDA前瞻性研究的预设二次分析,纳入2505例疑似心肌梗死患者,其中472例(20.8%)eGFR<60 mL/min/1.73 m²。
适用人群与场景
- 疑似心肌梗死的成人患者,就诊于29个城市急诊科(2015年4月至2016年4月)。
- 研究纳入2505例受试者,排除234例;最终分析人群以eGFR分层,其中472例(20.8%)eGFR<60 mL/min/1.73 m²。
诊断标准与关键阈值
- 主要终点为非ST段抬高型心肌梗死(NSTEMI),采用第三版心肌梗死通用定义,由对hs-cTn结果不知情的医生裁定。
- eGFR采用慢性肾脏病流行病学协作组(CKD-EPI)公式计算。
- 基线rule-in截断值:在eGFR<15 mL/min/1.73 m²患者中,120 ng/L对应特异性85.0%、阳性预测值62.5%;提高至600 ng/L后对应特异性93.3%、阳性预测值78.9%。
研究设计与关键结果
- 研究类型:FDA前瞻性研究的预设二次分析;样本量2505例(排除234例后分析),来自29个城市急诊科;人群为疑似心肌梗死成人。
- 采血时间点为急诊到达后0、1、2-3和6-9小时;记录cTn和eGFR。
- 主要终点NSTEMI由对hs-cTn结果不知情的医生裁定。
- 在eGFR<15 mL/min/1.73 m²患者中,基线rule-in截断值120 ng/L时特异性85.0%、阳性预测值62.5%,774例患者需进一步观察。
- 将截断值提高至600 ng/L后,整体及各eGFR亚组的特异性和阳性预测值均提高;eGFR<15 mL/min/1.73 m²者特异性93.3%、阳性预测值78.9%,需观察患者数增至79例。
证据类型、等级与局限
- 证据类型:前瞻性研究的预设二次分析(FDA研究)。
- 作者结论:eGFR调整的基线rule-in阈值(Siemens Atellica hs-cTnI)可提高特异性且敏感性相同。
- 局限:原文报告需在前瞻性队列中进一步研究,该队列应具有更高的肾脏病患病率。
对床旁实践的改变
- 对于疑似心肌梗死且eGFR<15 mL/min/1.73 m²的患者,作者认为采用eGFR调整的基线rule-in截断值600 ng/L(Siemens Atellica hs-cTnI)可提高特异性且敏感性相同。
- 提高截断值至600 ng/L后,需进一步观察的患者数增加(原文报告为79例),可能影响急诊流程。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: High-sensitivity cardiac troponin assays (hs-cTn) aid in diagnosis of myocardial infarction (MI). These assays have lower specificity for non-ST Elevation MI (NSTEMI) in patients with renal disease. Our objective was to determine an optimized cutoff for patients with renal disease.
METHODS: We conducted an a priori secondary analysis of a prospective FDA study in adults with suspected MI presenting to 29 academic urban EDs between 4/2015 and 4/2016. Blood was drawn 0, 1, 2-3, and 6-9 h after ED arrival. We recorded cTn and estimated glomerular filtrate rate (eGFR) by Chronic Kidney Disease Epidemiology Collaboration equation. The primary endpoint was NSTEMI (Third Universal Definition of MI), adjudicated by physicians blinded to hs-cTn results. We generated an adjusted hscTn rule-in cutoff to increase specificity.
RESULTS: 2505 subjects were enrolled; 234 were excluded. Patients were mostly male (55.7%) and white (57.2%), median age was 56 years 472 patients [20.8%] had an eGFR <60 mL/min/1.73 m2. In patients with eGFR <15 mL/min/1.73 m2, a baseline rule-in cutoff of 120 ng/L led to a specificity of 85.0% and Positive Predictive Value (PPV) of 62.5% with 774 patients requiring further observation. Increasing the cutoff to 600 ng/L increased specificity and PPV overall and in every eGFR subgroup (specificity and PPV 93.3% and 78.9%, respectively for eGFR <15 mL/min/1.73m2), while increasing the number (79) of patients requiring observation.
CONCLUSIONS: An eGFR-adjusted baseline rule-in threshold for the Siemens Atellica hs-cTnI improves specificity with identical sensitivity. Further study in a prospective cohort with higher rates of renal disease is warranted.
参考来源
- Limkakeng AT, Hertz J, Lerebours R, et al. Ideal high sensitivity troponin baseline cutoff for patients with renal dysfunction. Am J Emerg Med. 2020. PMID: 33071083. doi:10.1016/j.ajem.2020.06.072
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。